遼寧
Fig. 1. Generation of Mi3-EDIII nanoparticle vaccine.
Fig. 2. Antigenic profiling of Mi3-EDIII.
Fig. 3. Immunogenicity of Mi3-EDIII in C57BL/6 mice.
Fig. 4. Protective efficacy of Mi3-EDIII in challenged neonatal mice.
Fig. 5. Immunogenicity and protective efficacy of Mi3-EDIII in Ifnar1 C57BL/6 mice.
Fig. 6. ADE effects of immune sera on ZIKV or DENV infection in K562 cells.
Supplementary Fig. S1. Neutralizing activities of mAbs 7B3, 8D10 and 8-4.
Supplementary Fig. S2. SDS-PAGE analysis of recombinant E404.
Supplementary Fig. S3. Frequency of GC B cells among total B cells in ILNs at week 8.
歡迎來(lái)到醫(yī)食參考新媒體矩陣
2023年疫苗接種攻略
陽(yáng)過(guò)了，該怎么打疫苗？最全接種指導(dǎo)手冊(cè)來(lái)了
撰寫(xiě)| 中國(guó)病毒學(xué)英文版
校稿| Gddra編審| Hide / Blue sea
編輯 設(shè)計(jì)| Alice
特別聲明：以上內(nèi)容(如有圖片或視頻亦包括在內(nèi))為自媒體平臺(tái)“網(wǎng)易號(hào)”用戶上傳并發(fā)布，本平臺(tái)僅提供信息存儲(chǔ)服務(wù)。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
壹家言
